Dr. John G. Freund co-founded Skyline Ventures in 1997 and has served as a Partner at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. Previously, he co-founded Intuitive Surgical, a medical device company, and served on its Board of Directors.
Prior to Intuitive Surgical, Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment (acquired by Siemens), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners, and a General Partner at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department. Dr. Freund currently serves on the board of directors of Sutro Biopharma, Inc. (STRO) and SI-Bone, Inc. (SIBN). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including, Proteon Therapeutics, Inc. (PRTO), Tetraphase Pharmaceuticals, Inc. (TTPH), XenoPort, Inc. (XNPT) — where he was Chairman, Concert Pharmaceuticals, Inc. (CNCE), MAP Pharmaceuticals, Inc. (MAPP) and MAKO Surgical Corp. (MAKO). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative and is a member of the Therapeutics Advisory Council of Harvard Medical School. Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.
